Share This

Public company info - Consun Pharmaceutical Group Ltd. , 01681.HK
Input the stock code or the company name     Search  
 
 Profile   Information   Data   Financial Ratios   Profit Loss   Cash Flow   Balance   Earnings   Dividend 

Consun Pharmaceutical Group Ltd., 01681.HK - Company Profile
Chairman AN Meng
Share Issued (share) 814,000,000
Par Currency Hong Kong Dollar
Par Value 0.1
Industry Medicine
Corporate Profile Business Summary: The principal activities of the Group are manufacturing and sales of pharmaceuticals. Performance for the year: Revenue for the year ended 31 December 2020 amounted to RMB1,752,830,000, representing an increase of approximately 1.4% as compared with the year ended 31 December 2019. Profit for the year ended 31 December 2020 attributable to equity shareholders of the Company amounted to RMB498,788,000, representing an increase of approximately 524.9% as compared with the year ended 31 December 2019. Basic and diluted earnings per share for the year ended 31 December 2020 amounted to approximately RMB0.61 and RMB0.61 respectively, representing increases of approximately 577.8% and 577.8% respectively as compared with the same for the year ended 31 December 2019. Business Review In 2020, the Group’s operation was under greater pressure and risks due to the unexpected COVID-19 pandemic. Nonetheless, the Group remained resilient against adversity. In the face of challenges posed by the COVID-19 pandemic, Consun Pharmaceutical Group stood by the whole nation and came through. With years of intensive development, the Group's prescription drug business has established a solid foundation that allowed it to stay strong in times of turmoil. Following the launch of the reform of Yulin Pharmaceutical, the Group's OTC business adjusted strategies proactively and developed positive business momentum by consolidating business segments, lowering inventory and reducing overdue receivables. The good news is that the Group's Pain-relieving Antidiarrheal Capsules（緩痛止瀉軟膠囊）and Jigucao Capsules（雞骨草膠囊） were successfully included in the National Medical Insurance Drug Catalogue（國家醫保目 錄）, which provided extra room for the Group's future development. In 2020, the Group recorded a revenue of approximately RMB1.75 billion, representing an increase of approximately 1.4% over the same period last year. The Company recorded a profit attributable to its equity shareholders of approximately RMB0.5 billion, representing an increase of approximately 524.9% over the same period last year. After excluding the impairment of non-cash goodwill and intangible assets of RMB0.32 billion last year, the profit attributable to equity shareholders increased by approximately 23.5% year-on-year. In terms of business segments, sales revenue of Consun Pharmaceutical Segment amounted to approximately RMB1.50 billion, representing a year-on-year increase of approximately 6.8%. Sichuan and Shandong became the two provinces to have recently achieved a sales revenue of over RMB100 million. As of now, a total of five provinces have recorded a revenue of over RMB100 million, namely Beijing, Guangdong, Hebei, Sichuan and Shandong. Amongst which: The sales revenue of kidney medicines amounted to approximately RMB1.17 billion in 2020, representing a year-on-year increase of approximately 9.7%. Uremic Clearance Granules （尿毒清顆粒）, the Group’s flagship product admitted to Class A of the National Medical Insurance Drug Catalogue (new version), has been improving steadily with a leading market share in China’s modern Chinese medicine market for oral renal disease treatment. In particular, the primary medical market has recorded a rapid growth in sales and is developing into a new growth pillar for the Company. The sales revenue of medical contrast medium amounted to approximately RMB0.14 billion in 2020, representing a slight year-on-year decrease of approximately 3.0%. Nonetheless, Consun Pharmaceutical still maintained its market position in the field of contrast medium for magnetic resonance imaging and, more encouragingly, rolled out its Iopamidol Injection （碘帕醇注射液）under the imaging product series. The Group successfully held Iopamidol Launching Conference themed “Work Together for Health, Happiness and a Bright Future （攜手健康 快樂同行 亮顯未來）” in various provinces including Guangdong, Shandong, Liaoning, Hunan and Guangxi. With the Iopamidol Injection entering the clinical application stage, Consun Pharmaceutical started to provide high quality, value for money and reliable products and services in the field of CT contrast medium. Yulin Pharmaceutical Segment evolved from the “reform for survival” in the second half of 2019 and joined the “expedition to high-risk territories” in 2020. By actively adjusting business strategies, it consolidated business segments, lowered inventory and reduced overdue receivables. Its efforts did not go in vain and eventually bore fruit. In August 2020, Yulin Pharmaceutical commenced the entrusted production of the Uremic Clearance Granules. Through the arrangement, it created synergy from the production capacity of three bases and developed the new model for manufacture and sales in the same region. This boosted its efficiency to respond to market demand significantly and lowered various overall logistics costs. Meanwhile, the existing production capacity of Yulin Pharmaceutical was given full play, which led to excellent progress in lowering the amortization costs. Amazon’s Bezos once compared “tenants” to “short-term investors” and “homeowners” to “long-term investors” . According to him, “tenants” only focus on short-term gains without regard for the maintenance costs of the house, while “homeowners” strive to balance their long-term input and comfortableness. In the case of Yulin Pharmaceutical, Consun Pharmaceutical will aim for long-term comfortableness and spare no effort in planning for and promoting its development. Fundamental foreign sales remained stable and free from the impact of the pandemic. The Group has completed the registration and filing of Uremic Clearance Granules in Hong Kong and Indonesia. It will launch the product in the first half of 2021. The Yulin Zheng Gu Shui（玉林牌正骨水）, Shiduqing Capsule（濕毒清膠囊）and Jigucao Capsules obtained the Certificate of Export Commodity Brand, which has enhanced the influence of Yulin’s products in overseas markets. Prospects:

Information from the financial statements of listed companies

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.